Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Oncology Research and Treatment 2021;44,12:682–689. https://doi.org/10.1159/000520364
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2021
- Creator
-
Heimberg, Linda
Knop, Stefan
- DOI
-
10.1159/000520364
- URN
-
urn:nbn:de:bvb:20-opus-249773
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:46 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Heimberg, Linda
- Knop, Stefan
- Universität Würzburg
Time of origin
- 2021
Other Objects (12)
Sorafenib in patients with refractory or recurrent multiple myeloma
Multiple myeloma
S188: Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab
Editorial: Molecular imaging in multiple myeloma: an update and future perspectives
Sorafenib in patients with refractory or recurrent multiple myeloma
Multiple myeloma
S188: Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab
Editorial: Molecular imaging in multiple myeloma: an update and future perspectives
Sorafenib in patients with refractory or recurrent multiple myeloma
Multiple myeloma
S188: Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab